CircRNAs | Location | Technique/cohort | Method | Sample type | Expression in tumor | Roles | Biomarkers | AUC | Survival | Functions | Mechanism | Gene symbol | Pathway | References |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
circGFRA1 | cytoplasm | MDA-MB-231/PTX | qRT-PCR | MDA-MB-231/PTX | Up in MDA-MB-231/PTX | Oncogenic | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to PTX | Sponge miR-361-5p | TLR4 | NR | [50] |
circRPPH1 | cytoplasm | GSE101123/20 TNBC versus 20 N | qRT-PCR | TNBC tissues and cells | Up | Oncogenic | NR | NR | NR | Proliferation and metastasis | Sponge miR-556-5p | YAP1 | NR | [60] |
circSEPT9 | cytoplasm | RNA-seq of 4 TNBC versus 4 N/60 TNBC versus 60 N/ 80 TNBC | qRT-PCR, ISH | TNBC tissues and cells | Up | Oncogenic | Diagnosis and prognosis | 0.711 | OS | Proliferation, metastasis, apoptosis, and autophagy | Sponge miR-637 | LIF | NR | [49] |
circLARP4 | NR | 283 BC versus 283 N 65 TNBC versus 65 N | qRT-PCR | TNBC tissues and cells | Down | Antitumor | Prediction of therapy response | NR | NR | Inhibit the resistance of TNBC cells to DOX | NR | NR | NR | [89] |
circUSP42 | NR | RNA-seq of TNBC versus adjacent tissues/30 TNBC versus 30 N | qRT-PCR | TNBC tissues | Down | Antitumor | Prognosis | NR | OS, DFS | NR | NR | NR | NR | [98] |
circABCB10 | NR | MDA-MB-231/PTX | qRT-PCR | MDA-MB-231/PTX | Up in MDA-MB-231/PTX | Oncogenic | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to PTX | Sponge Let-7a-5p | DUSP7 | NR | [95] |
circCDYL | NR | BC versus N | qRT-PCR | BC tissues and TNBC cells | Down | Antitumor | NR | NR | NR | Proliferation, migration, and invasion | Sponge miR-190a-3p | TP53INP1 | NR | [61] |
circZEB1 | NR | 30 TNBC versus 30 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | NR | NR | NR | Proliferation and apoptosis | Sponge miR-448 | eEF2k | NR | [58] |
circGNB1 | cytoplasm | Microarray/222 TNBC | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-141-5p | IGF1R | NR | [59] |
hsa_circ_0131242 | NR | Microarray of TNBC versus normal tissues/30 TNBC versus 30 N /120 TNBC | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS | Proliferation and metastasis | Sponge miR-2682 | NR | NR | [79] |
circEIF3M | cytoplasm | RNA-seq of 3 TNBC versus 3 N /20 TNBC versus 20 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | NR | NR | NR | Proliferation, metastasis, cell cycle, and apoptosis | Sponge miR-33a | CCND1 | NR | [62] |
circHER2 | cytoplasm | RNA-seq of 5 TNBC versus 5 N /59 TNBC versus 59 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis and prediction of therapy response | NR | OS | Proliferation and invasion, circHER2 expressing TNBC are sensitive to Pertuzumab | Encode a novel HER2 variant HER2– 103 | HER2– 103 | Promote EGFR/HER3 interaction and activation | [75] |
circPGAP3 | cytoplasm | 86 TNBC versus 86 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS,DFS | Proliferation and metastasis | Sponge miR-330-3p | myc | NR | [64] |
circUBE2D2 | cytoplasm | 66 TNBC versus 66 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis and prediction of therapy response | NR | OS | Proliferation and metastasis, increase the resistance of TNBC cells to DOX | Sponge miR‑512‑3p | CDCA3 | NR | [63] |
circRAD18 | cytoplasm | Microarray of TNBC versus adjacent tissues/31 TNBC versus 31 N/126 TNBC | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Diagnosis and prognosis | 0.752 | OS | Proliferation, metastasis, and apoptosis | Sponge miR-208a/3164 | IGF1 and FGF2 | NR | [78] |
hsa_circ_0005320 | cytoplasm | RNA-seq of 4 TNBC versus 4 N/20 TNBC versus 20 N | RTFQ-PCR | TNBC tissue, cells | Up | Oncogenic | NR | NR | NR | proliferation, cell cycle, and apoptosis | NR | LIF、P-STAT3 | activate LIF-STAT3 pathway | [80] |
hsa_circ_069718 | NR | Microarray of TNBC versus adjacent tissues/35 TNBC versus 35 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS | Proliferation and invasion | NR | β-catenin, c-myc, and cyclin D1 | Activate Wnt/β-catenin pathway | [81] |
circFBXW7 | cytoplasm | 473 TNBC | RT-qPCR | TNBC tissue, cells | Down | Antitumor | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-197-3p and encode the FBXW7-185aa protein | FBXW7 | NR | [74] |
circCDR1as | NR | MDA-MB-231/5-Fu | RT-qPCR | MDA-MB-231/5-Fu | Up | Oncogenic | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to 5-FU | Sponge miR-7 | NR | NR | [97] |
circAGFG1 | cytoplasm | RNA-seq of 4 TNBC versus 4 N/40 TNBC versus 40 N/80 TNBC | RT-qPCR, ISH | TNBC tissue, cells | Up | Oncogenic | Diagnosis and prognosis | 0.767 | OS | Proliferation, metastasis, cell cycle, and apoptosis | Sponge miR-195-5p | CCNE1 | NR | [57] |
hsa_circ_0058514 | NR | RNA-seq of 4 TNBC versus 4 N/20 TNBC versus 20 N | RTFQ-PCR | TNBC tissue, cells | Up | Oncogenic | NR | NR | NR | Proliferation, metastasis, cell cycle, and apoptosis | NR | CCNE1 and CDK2 | NR | [82] |
circTADA2A-E6 | cytoplasm | Microarray of 8 specimens (4 TNBC and 4 luminal A) versus 3 normal tissues/178 BC versus 16 N /115 TNBC | RT-qPCR | TNBC tissue, cells | Down | Antitumor | Diagnosis and prognosis | 0.8554 | OS, DFS | Proliferation and metastasis | Sponge miR-203a-3p | SOCS3 | NR | [48] |
circAHNAK1 | cytoplasm | Microarrays/20 TNBC versus 20 N/136 TNBC | RT-qPCR | TNBC tissue, cells | Down | Antitumor | Diagnosis and prognosis | 0.72 | OS, DFS | Proliferation and metastasis | Sponge miR-421 | RASA1 | NR | [56] |
circITCH | NR | 275 BC versus 68 N/91 TNBC | RT-qPCR | TNBC tissue, cells | Down | Antitumor | Prognosis | NR | OS | Proliferation and metastasis | Sponge miR-214/ miR-17 | ITCH | Inactivate the Wnt/β-catenin pathway | [52] |
circTFCP2L1 | cytoplasm | Microarray of 3 TNBC versus 3 N/32 TNBC versus 32 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | DFS | Proliferation and migration | Sponge miR-7 | PAK1 | NR | [55] |
circKIF4A | cytoplasm | Microarray/240 TNBC | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-375 | KIF4A | NR | [51] |
circAMOTL1 | NR | MDA-MB-231/PTX | qRT-PCR | MDA-MB-231/PTX | Up in MDA-MB-231/PTX | Oncogenic | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to PTX | NR | BCL2, BAX and BAK | AKT pathway, | [96] |
circKDM4C | cytoplasm | MDA-MB-231/DOX | qRT-PCR | MDA-MB-231/DOX | Down MDA-MB-231/DOX | Antitumor | Prediction of therapy response | NR | NR | Decreased the resistance of TNBC cells to doxorubicin | Sponge miR-548p | PBLD | NR | [90] |
circPLK1 | cytoplasm | Microarray of four cell lines (MDA-MB-231, MDA-MB-468, BT549 versus MCF-10A)/57 TNBC versus 57 N/240 TNBC | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and metastasis | Sponge miR-296-5p | PLK1 | NR | [54] |
circANKS1B | cytoplasm | RNA-seq of 3 TNBC versus 3 N/20 TNBC versus 20 N/ 165 BC versus 40 N | RT-qPCR | BC tissue, cells | Up | Oncogenic | Prognosis | NR | OS | Invasion and metastasis | Sponge miR-148a/ 152-3p | USF1 | Activate of TGF-β1 signaling pathway | [47] |
circUBAP2 | cytoplasm | 78 TNBC versus 78 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS | Proliferation, metastasis, and apoptosis | Sponge miR-661 | MTA1 | NR | [53] |
circ-ciRS-7 | cytoplasm | 32 TNBC versus 32 N | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | NR | NR | NR | Invasion and metastasis | Sponge miR-1299 | MMPs | NR | [45] |
circMTO1 | nucleus | MDA-MB-231/monastrol | qRT-PCR | MDA-MB-231/monastrol | Down MDA-MB-231/ monastrol | Antitumor | Prediction of therapy response | NR | NR | Reverses the resistance of TNBC cells to monastrol | Binding to TRAF4 | Eg5 | NR | [67] |
circEPSTI1 | NR | Microarray of 3 TNBC versus 3 N/37 TNBC versus 30 N/240 TNBC | RT-qPCR, ISH | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and apoptosis | SPONGE miR-4753/6809 | BCL11A | NR | [46] |
circGFRA1 | cytoplasm | Microarray of TNBC cells and MCF-10A /51 TNBC versus 51 N/222 TNBC | RT-qPCR | TNBC tissue, cells | Up | Oncogenic | Prognosis | NR | OS, DFS | Proliferation and apoptosis | Sponge miR-34a | GFRA1 | NR | [29] |
hsa_circ_0006528 | NR | MDA-MB-231/DOX | qRT-PCR | MDA-MB-231/DOX | Up in MDA-MB-231/DOX | Oncogenic | Prediction of therapy response | NR | NR | Increase the resistance of TNBC cells to PTX | Sponge miR-7–5p | Raf1 | NR | [87] |